Innovative International Benchmark Framework for Pediatric Liver Transplantation Announced

Establishing New Standards in Pediatric Liver Transplantation

In an unprecedented global multicenter study, researchers have developed the first international benchmark framework aimed at optimizing pediatric liver transplantation outcomes. This landmark study, which was presented as a late-breaking clinical trial during the recent International Congress of the International Liver Transplantation Society (ILTS) in Geneva, marks a significant advancement in pediatric transplantation.

Conducted between 2000 and 2024, this study analyzed data from nine high-volume transplant centers across North America, Asia, Europe, South America, and Africa/Middle East. It addressed a crucial gap in pediatric transplantation: the lack of globally accepted benchmarks that define morbidity, complications, graft survival, and recipient outcomes in diverse pediatric populations.

Dr. Sapana Verma, the lead researcher, expressed the urgency of establishing these international benchmarks, saying, "Globally accepted benchmark standards for pediatric liver transplantation have been sorely lacking. Our goal has been to establish international benchmark reference standards for morbidity and survival after pediatric liver transplantation."

The results of the benchmark cohort revealed noteworthy improvements in transplantation outcomes, including significantly lower major morbidity rates, reduced occurrences of renal, vascular, and biliary complications, as well as shorter lengths of ICU admissions and hospital stays for patients. The newly established framework has shown to effectively differentiate outcomes among various pediatric subgroups, suggesting that the benchmarking model can be utilized for assessing global healthcare quality and for future risk-adjusted outcome analyses.

Moving forward, the research team plans to expand their study to include over 10,000 pediatric transplant recipients in order to create definitive global reference standards. These benchmarks will facilitate comprehensive outcome thresholds based on factors such as recipient age, weight, the etiology of liver disease, graft type, and combined risk profiles.

Don Webber, the President and CEO of Bridge to Life Ltd., highlighted the significance of this work by stating, "Pediatric transplantation has historically lacked the standardized reference points that exist in adult transplantation. It is imperative to establish these benchmarks as we advance toward precision graft assessments and developing optimized preservation strategies, including hypothermic oxygenated perfusion (HOPE)."

The study also explored the effectiveness of Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion System, proving its safety and efficacy in pediatric liver transplantation. This is a crucial insight as the field evolves towards more individualized graft selection processes and the increased application of advanced preservation technologies.

As pediatric transplantation continues to develop, these new benchmark standards are set to lay a crucial foundation for enhancing clinical decision-making. They not only define achievable outcomes but are also expected to improve access to safe transplantations for a broader range of pediatric patients globally. The advancements in preservation methods like HOPE represent a promising opportunity to enhance the viability of higher-risk grafts, thus ensuring more successful transplantation outcomes.

In conclusion, the international benchmark framework signifies a pivotal moment in pediatric liver transplantation, emphasizing the need for standardized processes while paving the way for future innovations and enhancements in patient care.

About Bridge to Life™ Ltd

Bridge to Life™ Ltd is a leader in organ preservation technologies, offering a range of innovative products such as Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. With a commitment to quality, innovation, and accessibility, Bridge to Life continues to partner with top transplant centers and organ procurement organizations worldwide.